Skip to content

KC PHARMA

Active Private limited companyfounded 2003active for 23 yearsLeeuwerikheide 86, 2400 MolKBO/BCE: BE 0479.334.705

Lifetime

20 annual accounts with figures on one time axis, 23 filings since 2003
peak of €228,758 in 2010
€158,741▲ 428%
peak of €945,370 in 2009
€115,605▲ 477%
peak of €736,030 in 2025
€736,030▲ 18.0%
€137,266▲ 25.8%
Board1 name since 2012
1 director
Documentsfilings and deeds
28-07-20263 days before the deadline
2025micro format
Gross margin from €30,046 to €158,741Result from €20,026 to €115,605Equity from €623,785 to €736,030Debts from €109,099 to €137,266Cash from €21,980 to €11,932

Key points

from the 2025 annual accounts

Equity

€736,030 ▲ 18.0%

KC PHARMA has made a profit in every financial year since 2006.

Result

€115,605 ▲ 477%
€20,0002024€116,0002025

The result rose in 2025 from €20,026 to €115,605.

Turnover

≈ €260,000 estimated

The accounts state no turnover.

Investments

€4,724 5.5 times depreciation
20212025

Green is investment, beige is depreciation.

Filings

23 annual accounts since 2003
AprilJune31 JulyOctober20102020

The 2016 accounts came 23 days late. The other nine of the last ten were filed on time.

Position in the sector

€736,030

More equity than 92% of companies in head offices and management consultancy. The sector median is €79,311, over 41,336 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,149 companies had the same profile as KC PHARMA has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,149 companies, not a prediction for KC PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 01-12-2023
  • deed of 30-12-2013

Shares in 1 company,

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0479334705
changes role from manager to director General meeting of 01-12-2023 · Gazette deed
Capital decrease of €420,000 to €36,500 The capital fell from €456,500 to €36,500 · Gazette deed
Registered office moved within Mol The registered office moved from Ginderbuiten 119, 2400 Mol to Leeuwerikheide 86, 2400 Mol · Gazette deed
All 37 events

Comparable companies

same main activity, similar in size and age
Company
KC PHARMA Mol €873,296 €158,741 84.3% -
MEZZANINE & PARTNERS Antwerp €862,968 €156,686 94.6% -
BOZI Zandhoven €884,836 €144,958 82.8% -
NETH-IMMO Grobbendonk €793,315 €152,705 39.4% -
GFB Mechelen €969,435 €172,476 30.3% 2.8
PICOTEC IMMO Stabroek €907,710 €139,424 12.9% -
VERREZEN FINANCIAL Westerlo €985,687 €180,164 63.5% -

These companies have the same main activity as KC PHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €793,000 and €986,000, founded between 2002 and 2004.

Official details

Source: KBO
Status
Active since 16-01-2003Normal situation
Activity
Business and other management consultancyNACE 70200and 1 other
Establishment unit
2.131.912.4212400 Mol, since 28-05-2003
Financial year end
31 December
Peppol
Reachable since 16-06-2026
Company details

Annual accounts 2025

€873,296▲ 19.2%
Filing
Filed on 28-07-2026, 3 days before the end of the filing period
Financials

Insights on KC PHARMA

KC PHARMA files the micro format. That format states no turnover. The gross margin rose from €133,899 in 2006 to €158,741 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about KC PHARMA

What is the company number of KC PHARMA?
The company number of KC PHARMA is 0479.334.705. The VAT number is the same number with BE in front: BE 0479.334.705.
Where is KC PHARMA based?
The registered office is at Leeuwerikheide 86, 2400 Mol.Company details
What does KC PHARMA do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of KC PHARMA?
KC PHARMA is a private limited company (BV).
When was KC PHARMA founded?
KC PHARMA was founded on 16-01-2003.
Is KC PHARMA still active?
Yes, KC PHARMA is an active enterprise in the KBO register.
What is the turnover of KC PHARMA?
The turnover in financial year 2025 is about €260,000. This figure is estimated from the gross margin of €158,741 and 123 comparable companies (NACE 70200). It probably lies between €230,000 and €310,000.Financials
Is KC PHARMA profitable?
In financial year 2025, KC PHARMA made a profit of €115,605.
Where can I find the annual accounts of KC PHARMA?
KC PHARMA filed 23 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of KC PHARMA due?
KC PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.